© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Dan Petrylak, MD, discusses 2 case studies that focus on metastatic castration-sensitive prostate cancer, with emphasis on the use of abiraterone to treat the disease.
January 26th 2022
Dan Petrylak, MD, presents our first case for discussion, an 80-year-old man with metastatic castration-sensitive prostate cancer (mCSPC). Front-line therapy options and monitoring for mCSPC are also mentioned.
Dr Petrylak recalls the study design and results of the TITAN study.
An expert explains the unmet needs in the mCSPC landscape, as well as key takeaways if you are treating patients with this disease.
Dr Petrylak presents our second case, a 62-year-old man with mCSPC.
Dan Petrylak, MD, discusses the pros and cons of using abiraterone as a front-line therapy for mCSPC and provides details of the PEACE-1 study.